Table 3.

Multivariable analysis^‖ of comparative effectiveness of infliximab and adalimumab in inflammatory bowel disease

	Odds Ratio [(for ADA vs. IFX(ref)]	95% confidence interval (CI)
Crohn’s disease
Narrative outcomes
Symptomatic non-response score at 1 year	1.62	1.21 – 2.17
Codified outcomes
Composite outcome	1.17	0.86 – 1.60
Surgery	1.28	0.73 – 2.24
Hospitalization	1.01	0.72 – 1.42
Prednisone prescription	1.29	0.92 – 1.81
Normalization of CRP	1.13	0.72 – 1.78
Ulcerative colitis	Odds Ratio [(for ADA vs. IFX(ref)]	95% CI
Narrative outcomes
Symptomatic non-response score at 1 year	1.53	0.86 – 2.73
Codified outcomes
Composite outcome	0.72	0.40 – 1.29
Surgery	0.99	0.43 – 2.25
Hospitalization	1.32	0.70 – 2.47
Prednisone prescription	0.66	0.36 – 1.20
Normalization of CRP	1.13	0.72 – 1.78

CRP – C-reactive protein

^†available for 309 CD patients with IFX; 212 CD patients with ADA; 195 UC patients with IFX, 53 UC patients with ADA

^‖Adjusted for interval between first IBD diagnosis code and anti-TNF start date, gender, prior surgery or hospitalization, prior anti-TNF use, and combination immunomodulator therapy. Additionally adjusted for perianal involvement and penetrating phenotype in CD